StoxDivi's Laboratories vs Torrent Pharmaceuticals: share price & financials comparison
NSE: DIVISLAB vs TORNTPHARM · Healthcare · as of 06 Nov 2026
Both prices rebased to 100 at the start of the selected period.
Divi's Laboratories vs Torrent Pharmaceuticals at a glance
Divi's Laboratories (DIVISLAB) has a market capitalisation of ₹2,73,493 Cr, against ₹1,80,671 Cr for Torrent Pharmaceuticals (TORNTPHARM). Over the past year Divi's Laboratories has returned +58.5%, compared with +32.0% for Torrent Pharmaceuticals. On valuation, Torrent Pharmaceuticals trades at a lower P/E of 85.1 versus 93.5. Divi's Laboratories earns a higher return on equity (17.5% vs 11.6%). Divi's Laboratories comes out ahead on size, profitability, growth, momentum and technicals. Torrent Pharmaceuticals comes out ahead on valuation. Across the scored metrics below, Divi's Laboratories leads on 12 and Torrent Pharmaceuticals on 5. On StoxGud's 10-point checklist, Divi's Laboratories scores 8/10 and Torrent Pharmaceuticals scores 7/10.
| Metric | Divi's Laboratories | Torrent Pharmaceuticals |
|---|---|---|
| Size | ||
| Market cap | ₹2,73,493 Cr | ₹1,80,671 Cr |
| Revenue (latest FY) | ₹10,560 Cr | ₹13,980 Cr |
| Net profit (latest FY) | ₹2,568 Cr | ₹2,163 Cr |
| Valuation | ||
| P/E | 93.5 | 85.1 |
| P/B | 16.32 | 9.83 |
| Dividend yield | 0.29% | 0.71% |
| Profitability | ||
| Return on equity | 17.5% | 11.6% |
| Net profit margin | 26.0% | 12.2% |
| Operating margin | 35.3% | 33.2% |
| Growth | ||
| Revenue growth (YoY) | +27.8% | +50.8% |
| Net profit growth (YoY) | +65.5% | -9.6% |
| Revenue CAGR (multi-year) | +11.8% | +11.8% |
| Financial health | ||
| Debt to equity | 0.00 | 0.76 |
| Momentum | ||
| 1-month return | +7.6% | +0.7% |
| 1-year return | +58.5% | +32.0% |
| 3-year CAGR | +43.3% | +34.2% |
| 5-year CAGR | +16.1% | +26.8% |
| 10-year CAGR | +23.3% | +21.7% |
| Distance from 52W high | +0.0% | -7.3% |
| Technicals | ||
| RSI (14) | 82 | 66 |
| Price vs 200-day avg | +39.4% | +4.9% |
Highlighted cells lead on that metric. Market cap, revenue and RSI are shown for context and not scored.
10-point checklist side by side
| Check | Divi's Laboratories | Torrent Pharmaceuticals |
|---|---|---|
| Price above 50-day average | ✓ | ✗ |
| Price above 200-day average | ✓ | ✓ |
| 50-day average above 200-day (uptrend) | ✓ | ✓ |
| RSI in healthy 40–70 zone | ✗ | ✓ |
| Positive 1-year return | ✓ | ✓ |
| Return on equity above 15% | ✓ | ✗ |
| Debt to equity below 1 | ✓ | ✓ |
| Revenue growing year on year | ✓ | ✓ |
| Net profit margin above 10% | ✓ | ✓ |
| P/E below industry median | ✗ | ✗ |
| Score | 8/10 | 7/10 |
A rules-based screen for education only — not a buy or sell recommendation.
FAQs
Which is bigger, Divi's Laboratories or Torrent Pharmaceuticals?
Divi's Laboratories has a market cap of ₹2,73,493 Cr and Torrent Pharmaceuticals has a market cap of ₹1,80,671 Cr as of 06 Nov 2026.
Which has a lower P/E, Divi's Laboratories or Torrent Pharmaceuticals?
Torrent Pharmaceuticals has the lower P/E: Divi's Laboratories trades at 93.5 and Torrent Pharmaceuticals at 85.1.
Which gave better returns in the last year, Divi's Laboratories or Torrent Pharmaceuticals?
Divi's Laboratories did better: Divi's Laboratories returned +58.5% and Torrent Pharmaceuticals returned +32.0% over one year.
Is Divi's Laboratories or Torrent Pharmaceuticals a better buy?
StoxGud does not give buy or sell recommendations. On our rules-based checklist Divi's Laboratories scores 8/10 and Torrent Pharmaceuticals scores 7/10; compare valuation, profitability, growth and momentum above and consult a SEBI-registered adviser.